Cargando…
Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
Muscular dystrophies are characterized by weakness and wasting of skeletal muscle tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to increase muscle mass and function but most showed limited efficacy. Here we show that the expression of components of the myos...
Autores principales: | Mariot, Virginie, Joubert, Romain, Hourdé, Christophe, Féasson, Léonard, Hanna, Michael, Muntoni, Francesco, Maisonobe, Thierry, Servais, Laurent, Bogni, Caroline, Le Panse, Rozen, Benvensite, Olivier, Stojkovic, Tanya, Machado, Pedro M., Voit, Thomas, Buj-Bello, Ana, Dumonceaux, Julie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709430/ https://www.ncbi.nlm.nih.gov/pubmed/29192144 http://dx.doi.org/10.1038/s41467-017-01486-4 |
Ejemplares similares
-
Myostatin Is a Quantifiable Biomarker for Monitoring Pharmaco-gene Therapy in Duchenne Muscular Dystrophy
por: Mariot, Virginie, et al.
Publicado: (2020) -
A Deoxyribonucleic Acid Decoy Trapping DUX4 for the Treatment of Facioscapulohumeral Muscular Dystrophy
por: Mariot, Virginie, et al.
Publicado: (2020) -
Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
por: Zhou, Haiyan, et al.
Publicado: (2020) -
RIPK3‐mediated cell death is involved in DUX4‐mediated toxicity in facioscapulohumeral dystrophy
por: Mariot, Virginie, et al.
Publicado: (2021) -
Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies
por: Baig, Mohammad Hassan, et al.
Publicado: (2022)